{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:58:24Z","timestamp":1781647104156,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ajt.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:04:05Z","timestamp":1757660645000},"page":"140-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Off-label use of alemtuzumab, belatacept, and rapamycin in kidney transplantation\u2014Long-term real-world experience"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3581-9550","authenticated-orcid":false,"given":"Kateryna","family":"Krynychka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4780-4156","authenticated-orcid":false,"given":"Goni","family":"Katz-Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-3129","authenticated-orcid":false,"given":"Jennifer S.","family":"Byrns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-6549","authenticated-orcid":false,"given":"Brian I.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nrupen A.","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2838-3918","authenticated-orcid":false,"given":"Ursula","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-2944","authenticated-orcid":false,"given":"Annette M.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunrong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-5962","authenticated-orcid":false,"given":"Allan D.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajt.2025.09.004_bib1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/01.TP.0000119349.70491.F9","article-title":"Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients","volume":"77","author":"Baid-Agrawal","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ajt.2025.09.004_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1432-2277.2008.00640.x","article-title":"Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation","volume":"21","author":"Roland","year":"2008","journal-title":"Transpl Int"},{"issue":"12 Suppl 3","key":"10.1016\/j.ajt.2025.09.004_bib3","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1681\/ASN.2006080929","article-title":"New-onset diabetes after kidney transplantation: risk factors","volume":"17","author":"Rodrigo","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.004_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2000.tb01004.x","article-title":"Neurotoxicity of calcineurin inhibitors: impact and clinical management","volume":"13","author":"Bechstein","year":"2000","journal-title":"Transpl Int."},{"key":"10.1016\/j.ajt.2025.09.004_bib5","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1038\/ki.2010.426","article-title":"Optimal immunosuppression to prevent chronic allograft dysfunction","volume":"119","author":"Griny\u00f3","year":"2010","journal-title":"Kidney Int Suppl"},{"issue":"2S1","key":"10.1016\/j.ajt.2025.09.004_bib6","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ajt.2024.01.012","article-title":"OPTN\/SRTR 2022 annual data report: kidney","volume":"24","author":"Lentine","year":"2024","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.004_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","article-title":"Incidence and long-term cost of steroid-related side effects after renal transplantation","volume":"33","author":"Veenstra","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.ajt.2025.09.004_bib8","article-title":"Steroid avoidance or withdrawal for kidney transplant recipients","author":"Haller","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.004_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2019040416","article-title":"Early steroid withdrawal in deceased-donor kidney transplant recipients with delayed graft function","volume":"31","author":"Bae","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ajt.2025.09.004_bib10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"issue":"5 Pt 1","key":"10.1016\/j.ajt.2025.09.004_bib11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1600-6143.2006.01259.x","article-title":"A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression","volume":"6","author":"Larsen","year":"2006","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.004_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2025.09.004_bib13","first-page":"355","article-title":"Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection","volume":"6","author":"Ippoliti","year":"2012","journal-title":"Biologics"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.004_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.004_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajt.2025.09.004_bib16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.ekir.2023.08.037","article-title":"Costimulatory blockade and solid organ transplantation: the past, present, and future","volume":"8","author":"Kitchens","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1016\/j.ajt.2025.09.004_bib17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1111\/ajt.16152","article-title":"Avoidance of CNI and steroids using belatacept\u2014results of the Clinical Trials in Organ Transplantation 16 trial","volume":"20","author":"Mannon","year":"2020","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2025.09.004_bib18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2215\/CJN.15040920","article-title":"Long-term immunosuppression management: opportunities and uncertainties","volume":"16","author":"Wojciechowski","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.004_bib19","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2025.09.004_bib20","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1111\/ajt.16121","article-title":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: five-year follow-up","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.004_bib21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/ajt.16386","article-title":"Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients","volume":"21","author":"Kirk","year":"2021","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.004_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.ajt.2025.09.004_bib23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/15260","article-title":"Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance","volume":"5","author":"Wells","year":"1999","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.004_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-6143.2012.04342.x","article-title":"Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion","volume":"13","author":"Lo","year":"2013","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.004_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.TP.0000071362.99021.D9","article-title":"Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H)","volume":"76","author":"Kirk","year":"2003","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.ajt.2025.09.004_bib26","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/01.tp.0000296680.75175.67","article-title":"Alemtuzumab","volume":"84","author":"Weaver","year":"2007","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.ajt.2025.09.004_bib27","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/15256","article-title":"Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance","volume":"5","author":"Li","year":"1999","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ajt.2025.09.004_bib28","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.4049\/jimmunol.2000736","article-title":"Functional characteristics and phenotypic plasticity of CD57+PD1\u2212 CD4 T cells and their relationship with transplant immunosuppression","volume":"206","author":"Shaw","year":"2021","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.ajt.2025.09.004_bib29","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ajt.2025.09.004_bib30","first-page":"2600","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajt.2025.09.004_bib31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2025.09.004_bib32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1681\/ASN.2018111101","article-title":"Long-term outcomes after acute rejection in kidney transplant recipients: an ANZDATA analysis","volume":"30","author":"Clayton","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.004_bib33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.34067\/KID.0007342021","article-title":"Clinical events and renal function in the first year predict long-term kidney transplant survival","volume":"3","author":"Schold","year":"2022","journal-title":"Kidney360"},{"issue":"4","key":"10.1016\/j.ajt.2025.09.004_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.15688","article-title":"Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial","volume":"20","author":"Woodle","year":"2020","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.004_bib35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2014040326","article-title":"Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival","volume":"27","author":"Guidicelli","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ajt.2025.09.004_bib36","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.004_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2215\/CJN.00700117","article-title":"Donor-specific antibodies in kidney transplant recipients","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ajt.2025.09.004_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1747030","article-title":"De novo donor-specific HLA antibodies developing early or late after transplant are associated with the same risk of graft damage and loss in nonsensitized kidney recipients","volume":"2017","author":"Cioni","year":"2017","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.ajt.2025.09.004_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajt.15585","article-title":"The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients","volume":"20","author":"Parsons","year":"2020","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2025.09.004_bib40","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/ajt.14738","article-title":"Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: post hoc analyses of BENEFIT and BENEFIT-EXT","volume":"18","author":"Bray","year":"2018","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.ajt.2025.09.004_bib41","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2025.09.004_bib42","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/TP.0b013e31822805d7","article-title":"Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal","volume":"92","author":"Heilman","year":"2011","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ajt.2025.09.004_bib43","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled Trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ajt.2025.09.004_bib44","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/TP.0000000000002769","article-title":"Mammalian target of rapamycin inhibitors combined with calcineurin inhibitors as initial immunosuppression in renal transplantation: a meta-analysis","volume":"103","author":"Montero","year":"2019","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.004_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","article-title":"Human cytomegalovirus and kidney transplantation: a clinician\u2019s update","volume":"58","author":"De Keyzer","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ajt.2025.09.004_bib46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16132","article-title":"CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept","volume":"21","author":"Karadkhele","year":"2021","journal-title":"Am J Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525029557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613525029557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:35:19Z","timestamp":1778621719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613525029557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1600613525029557"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2025.09.004","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label use of alemtuzumab, belatacept, and rapamycin in kidney transplantation\u2014Long-term real-world experience","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}